Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             187 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Author index 2005
 29 S1 p. S73-S78
6 p.
 artikel
2 Committees 2005
 29 S1 p. iv-
1 p.
 artikel
3 O-32 Aberrant expression of YB-1 gene in erythroid cells in myelodysplastic syndrome Harigae, H.
 2005
 29 S1 p. S11-S12
2 p.
 artikel
4 O-59 Allogeneic stem celltransplantation for patients with myelodysplastic syndrome (MDS). Results of the Japan society for hematopoietic cell transplantation (JSHCT) Okamoto, S.
 2005
 29 S1 p. S21-
1 p.
 artikel
5 O-31 A mouse model for human MDS:NUP98-HOXD13 transgenic mice develop MDS that evolve to acute leukemia Lin, Y.-W.
 2005
 29 S1 p. S11-
1 p.
 artikel
6 O-14 A reversible two-step model ofMDS/preleukemia: Transgenic mice expressing inducible BCL2 and mutant NRAS Padua, R.A.
 2005
 29 S1 p. S5-
1 p.
 artikel
7 O-55 Arsenic trioxide: A novel approachto the treatment of MDS Vey, N.
 2005
 29 S1 p. S19-
1 p.
 artikel
8 O-10 Bmi-1 expression predicts the progression of leukemic stem cells and prognosis in myelodysplastic syndrome Mihara, K.
 2005
 29 S1 p. S3-S4
2 p.
 artikel
9 O-15 CD45-negative clonal cellswith very immature phenotype (CD45-CD34-CD38-Lin-) in patients with myelodysplastic syndromes Ogata, K.
 2005
 29 S1 p. S5-
1 p.
 artikel
10 O-69 Characteristics of therapy-relatedMDS in 133 patients Knipp, S.
 2005
 29 S1 p. S23-
1 p.
 artikel
11 O-51 Chelation therapy inmyelodysplastic syndrome: Update from recent clinical trials with oral agents Gattermann, N.
 2005
 29 S1 p. S18-
1 p.
 artikel
12 O-67 Comparison of “high” and“low” intensity approaches for high-risk MDS Estey, E.
 2005
 29 S1 p. S23-
1 p.
 artikel
13 O-33 Cryogenetic profile in 2124 patientswith MDS — Correlations with morphology, clinical course and prognosis Haase, D.
 2005
 29 S1 p. S12-
1 p.
 artikel
14 O-23 Cytogenetic and clinical features of unbalanced translocation der(1;7)(g10;p10) in myelodysplastic syndromes Sanada, M.
 2005
 29 S1 p. S8-
1 p.
 artikel
15 O-36 Diagnosis of immune pathophysiology in patients with myelodysplastic syndrome Nakao, S.
 2005
 29 S1 p. S13-
1 p.
 artikel
16 O-42 Diagnostic pitfalls in childhoodMDS and JMML Hasle, H.
 2005
 29 S1 p. S14-S15
2 p.
 artikel
17 O-19 Diagnostic value of array-based CGH in MDS Maciejewski, J.P.
 2005
 29 S1 p. S7-
1 p.
 artikel
18 O-7 Difference in clinical featuresbetween Japanese and German patients with refractory anemia according to the French-American-British classification Matsuda, A.
 2005
 29 S1 p. S2-S3
2 p.
 artikel
19 O-16 Different CLIP (class II-associated invariant chain peptide) expression on CD7+ and CD7- hematopoietic precursor cell subpopulations in low-risk MDS van de Loosdrecht, A.A.
 2005
 29 S1 p. S6-
1 p.
 artikel
20 O-28 DNA microarray analysis ofmyelodysplastic syndromes with purified CD133-positive stem cell fractions Mano, H.
 2005
 29 S1 p. S10-
1 p.
 artikel
21 O-30 Dysplastic definitive hematopoiesis in AML1/Evi-1 knock-in embryos Mitani, K.
 2005
 29 S1 p. S11-
1 p.
 artikel
22 O-1 Environmental and molecularepidemiology of myelodysplastic syndromes Bowen, D.T.
 2005
 29 S1 p. S1-
1 p.
 artikel
23 O-2 Epidemiology of myelodysplasticsyndromes among Nagasaki atomic bomb survivors Iwanaga, M.
 2005
 29 S1 p. S1-
1 p.
 artikel
24 O-54 Epigenetic therapy for MDS Wijermans, P.W.
 2005
 29 S1 p. S19-
1 p.
 artikel
25 O-11 Ex vivo expansion of humanhematopoietic stem cells Nakahata, T.
 2005
 29 S1 p. S4-
1 p.
 artikel
26 O-9 Familial myelodysplastic syndromein 4 patients with normal karyotype Kuendgen, A.
 2005
 29 S1 p. S3-
1 p.
 artikel
27 O-21 Gene expression profiling of thebone marrow mononuclear cells from patients with myelodysplastic syndrome Chen, Z.
 2005
 29 S1 p. S7-S8
2 p.
 artikel
28 O-29 Genome-wide high-resolution analysis of DNA copy number changes in myelodysplastic syndromes using high-density oligonucleotide SNP genotyping arrays Ogawa, S.
 2005
 29 S1 p. S10-S11
2 p.
 artikel
29 O-24 Global hyper di-methylation ofhistone H3 lysine 9 in neutrophils of myelodysplastic syndrome patients with −7/complex chromosomal abnormalities Ishikawa, M.
 2005
 29 S1 p. S9-
1 p.
 artikel
30 O-38 Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013; revlimid) in transfusion dependent (TD) MDS with chromosome 5Q31.1 deletion: Results of the multicenter MDS-003 study List, A.F.
 2005
 29 S1 p. S14-
1 p.
 artikel
31 O-13 Hematopoietic stem cells in normaland preleukemic disease states Eaves, C.
 2005
 29 S1 p. S4-S5
2 p.
 artikel
32 O-56 Hematopoietic stem cell strategiesin patients with myelodysplastic syndrome and secondary acute myeloid leukemia: The role of reduced intensity conditioning regimens De Witte, T.M.
 2005
 29 S1 p. S20-
1 p.
 artikel
33 O-57 Hemopoietic cell transplantationfor the treatment of MDS Deeg, H.J.
 2005
 29 S1 p. S20-
1 p.
 artikel
34 O-46 Heterogeneity of clinical featuresand outcomes of patients with abnormal cytogenetic clones evolving from aplastic anemia Ohara, A.
 2005
 29 S1 p. S16-
1 p.
 artikel
35 O-71 High response rate to darbopoetin alpha and sustained response in low risk MDS Mannone, L.
 2005
 29 S1 p. S24-
1 p.
 artikel
36 O-34 Immunosuppressive therapy withATG in low-risk patients with myelodysplastic syndrome Molldrem, J.J.
 2005
 29 S1 p. S12-S13
2 p.
 artikel
37 O-22 Incidence of cytogenetic response in MDS/AML patients with complex karyotype receiving low-dose 5-aza-2′deoxycytidine (decitabine) treatment Lubbert, M.
 2005
 29 S1 p. S8-
1 p.
 artikel
38 O-44 Juvenile myelomonocytic leukemia (JMML): From clinical examination to molecular genetics Niemeyer, C.M.
 2005
 29 S1 p. S15-
1 p.
 artikel
39 O-40 Lenalidomide inhibits proliferation of chromosome 5 mutant hematopoietic tumor cells and interferes with adaptor protein complex assembly and phosphorylation Krithivas Gandhi, A.
 2005
 29 S1 p. S14-
1 p.
 artikel
40 O-49 Management of the anemia of MDS Hellström-Lindberg, E.
 2005
 29 S1 p. S17-S18
2 p.
 artikel
41 O-8 Measurement of telomere length inpatients with early MDS may serve as a prognostic factor Sieglova, Z.
 2005
 29 S1 p. S3-
1 p.
 artikel
42 O-18 MEF regulates the quiescence of primitive hematopoietic progenitor cells and their susceptibility to myelosuppression Nimer, S.D.
 2005
 29 S1 p. S6-
1 p.
 artikel
43 O-61 Molecular analysis of CTL responses in myelodysplastic syndrome and other bone marrow failure states Wlodarski, M.W.
 2005
 29 S1 p. S21-S22
2 p.
 artikel
44 O-62 Monocyte-derived dendriticcells from mds patients are able to induce T-lymphocytes proliferation, but not cell-mediated cytotoxicity — where is the problem? Neuwirtova, R.
 2005
 29 S1 p. S22-
1 p.
 artikel
45 O-50 New non-invasive methods formonitoring iron overload: Clinical use in MDS — MRI, squid vs. ferritin assessment Jensen, P.D.
 2005
 29 S1 p. S18-
1 p.
 artikel
46 O-53 New therapies in myelodysplasticsyndrome Stone, R.M.
 2005
 29 S1 p. S19-
1 p.
 artikel
47 O-20 Noninvasive detection ofmyelodysplastic syndromes using serum proteome profiling Aivado, M.
 2005
 29 S1 p. S7-
1 p.
 artikel
48 O-35 Outcome of immunosuppressivetherapy (IST) for myelodysplastic syndromes (MDS): Results of 21 cases from a single institution Tsushima, H.
 2005
 29 S1 p. S13-
1 p.
 artikel
49 O-58 Outcomes after umbilical-cord blood transplantation from unrelated donors (UCBT) in patients with myelodysplastic syndromes (MDS). A Eurocord study Sanz, G.F.
 2005
 29 S1 p. S20-
1 p.
 artikel
50 O-47 Palliative care and myelodysplasia: The importance of a “both/and” approach Quill, T.E.
 2005
 29 S1 p. S16-S17
2 p.
 artikel
51 O-43 Pediatric myelodysplastic syndromes (MDS) other than juvenile myelomonocytic leukemia (JMML) Manabe, A.
 2005
 29 S1 p. S15-
1 p.
 artikel
52 O-12 Priming of transcription factorsand hematopoietic cell fate decision Akashi, K.
 2005
 29 S1 p. S4-
1 p.
 artikel
53 O-25 Reversing gene silencing in myelodysplastic syndromes Nimer, S.D.
 2005
 29 S1 p. S9-
1 p.
 artikel
54 O-3 Risk factors for myelodysplastic syndrome and leukemia after breast cancer: Results of a French multicenter case-control study Fenaux, P.
 2005
 29 S1 p. S2-
1 p.
 artikel
55 O-4 Role of AML1/RUNX1 in the molecularpathogenesis of MDS Kimura, A.
 2005
 29 S1 p. S2-
1 p.
 artikel
56 O-66 Role of high-intensity therapyfollowed by G-CSF for patients with advanced myelodysplastic syndrome Yano, S.
 2005
 29 S1 p. S22-
1 p.
 artikel
57 O-26 Studies in MDS Koeffler, H.P.
 2005
 29 S1 p. S9-
1 p.
 artikel
58 O-27 Telomere dysfunction in myelodysplastic syndromes Ohyashiki, J.H.
 2005
 29 S1 p. S10-
1 p.
 artikel
59 O-17 Thalidomide analogue CC5013 (revlimid) selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5Q deletion Jadersten, M.
 2005
 29 S1 p. S6-
1 p.
 artikel
60 O-68 The role of chemotherapy in the treatment of myelodysplastic syndromes Ganser, A.
 2005
 29 S1 p. S23-
1 p.
 artikel
61 O-48 Treatment and biology of iron overload in myelodysplastic syndromes: New oral iron chelating agents Greenberg, P.
 2005
 29 S1 p. S17-
1 p.
 artikel
62 O-45 Treatment for patients relapsingwith juvenile myelomonocytic leukemia after allogeneic stem cell transplantation: The EWOG-MDS study Yoshimi, A.
 2005
 29 S1 p. S16-
1 p.
 artikel
63 O-37 Treatment of patients withmyelodysplastic syndrome with cyclosporin A Chen, S.
 2005
 29 S1 p. S13-
1 p.
 artikel
64 O-70 Vitamin K2 therapy in low-riskmyelodysplastic syndrome: A prospective Japanese study Miyazawa, K.
 2005
 29 S1 p. S24-
1 p.
 artikel
65 O-60 WT1 (Wilms' tumor gene) peptide-based immunotherapy for myelodysplastic syndrome Sugiyama, H.
 2005
 29 S1 p. S21-
1 p.
 artikel
66 P-58 Aberrant alternative splicing of interferon regulatory factor-1 (IRF-1) in myelodysplastic hematopoietic progenitor cells Maratheftis, C.I.
 2005
 29 S1 p. S46-
1 p.
 artikel
67 P-41 Aberrant mitochondrial iron distribution and maturation arrest characterizes early erythroid precursors in low-risk myelodysplastic syndromes Tehranchi, R.
 2005
 29 S1 p. S39-
1 p.
 artikel
68 P-95 Acute myeloid leukemia (AML)-type chemotherapy for newly diagnosed children with myelodysplastic syndrome (MDS): A Japanese childhood MDS study group trial MDS99 Ohtsuka, Y.
 2005
 29 S1 p. S60-
1 p.
 artikel
69 P-119 Advanced myelodysplastic syndromes (MDS): Patient subset results of a phase III trial comparing decitabine (DAC) vs. supportive care (SC) Saba, H.I.
 2005
 29 S1 p. S69-S70
2 p.
 artikel
70 P-96 Allogeneic haematopoietic celltransplantation in children with MDS — Single center experience Kalwak, K.
 2005
 29 S1 p. S60-
1 p.
 artikel
71 P-104 Allogeneic hematopoietic stem cell transplantation for MDS Liu, K.-y.
 2005
 29 S1 p. S63-S64
2 p.
 artikel
72 P-100 Allogeneic hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) evolved from aplastic anemia (AA) in childhood Kikuchi, A.
 2005
 29 S1 p. S62-
1 p.
 artikel
73 P-103 Allogeneic stem cell transplantation for Fanconi anemia with leukemic transformation Yabe, M.
 2005
 29 S1 p. S63-
1 p.
 artikel
74 P-18 A new prognostic score foroutcome of patients with high-risk myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (SAML) after intensive antileukemic treatment Oosterveld, M.
 2005
 29 S1 p. S31-
1 p.
 artikel
75 P-89 An infant with radio-ulnarsynostosis and myelodysplastic syndrome (RCMD) had trisomy 8 and responded to immunosuppressive therapy Yano, M.
 2005
 29 S1 p. S58-
1 p.
 artikel
76 P-20 Application of who classification in Chinese patients with primary myelodysplastic syndromes Xiao, Z.
 2005
 29 S1 p. S31-S32
2 p.
 artikel
77 P-72 A prospective study using cyclosporin a for low-risk myelodysplastic syndrome Ishikawa, T.
 2005
 29 S1 p. S51-
1 p.
 artikel
78 P-65 Autoimmune and bleeding manifestations in a case of RAEB-1 with trisomy 8 Feitosa Pinheiro, R.
 2005
 29 S1 p. S48-S49
2 p.
 artikel
79 P-57 Autoimmune manifestations inhuman myelodysplasia. A positive correlation with interferon regulatory factor-1 (IRF-1) expression Giannouli, S.
 2005
 29 S1 p. S46-
1 p.
 artikel
80 P-55 5 Azacytidine in myelodysplasticsyndromes: Correlation between clinical responses and CDKN2B promoter methylation Rai, K.
 2005
 29 S1 p. S45-
1 p.
 artikel
81 P-115 Bisphosphonate zoledronicacid (ZOL) inhibits the abnormal proliferation and differentiation of juvenile myelomonocytic leukemia (JMML) cells Ohtsuka, Y.
 2005
 29 S1 p. S68-
1 p.
 artikel
82 P-56 CDKN2B (Pl5INK4B) and CDKN1A(P21CIP1) promoter hypermethylation occurs in lymphocytes and not in CD34+ or CD33+ myeloid cells of MDS patients John, A.
 2005
 29 S1 p. S45-
1 p.
 artikel
83 P-86 Changes of subsets of Th cellsand DC1 in the bone marrow of severe aplastic anemia and myelodysplastic syndrome He, G.
 2005
 29 S1 p. S56-S57
2 p.
 artikel
84 P-6 Characteristics of myelodysplastic syndromes in patients under 50 years of age Kuendgen, A.
 2005
 29 S1 p. S26-
1 p.
 artikel
85 P-66 Characteristics ofmyelodysplastic syndromes with der(1;7)(q10;p10): Report of 19 cases from Japan Hsiao, H.-H.
 2005
 29 S1 p. S49-
1 p.
 artikel
86 P-82 Chemokine expression in human erythroid leukemia cell line, AS-E2: Macrophage inflammatory protein-3α is induced by proinflammatory cytokines Inoue, Y.
 2005
 29 S1 p. S55-
1 p.
 artikel
87 P-69 Chromosome abnormalities in Chinese patients with primary myelodysplastic syndromes Xiao, Z.
 2005
 29 S1 p. S50-
1 p.
 artikel
88 P-15 Chronic myelomonocytic leukemia:IPSS best discriminates patients with worse prognosis, in both the dysplastic and the proliferative subtype Symeonidis, A.S.
 2005
 29 S1 p. S30-
1 p.
 artikel
89 P-70 Clinical and molecular cytogeneticstudies in eight patients with myeloid diseases characterized by idic(20)(p11)del(20) (q11q13) Li, T.
 2005
 29 S1 p. S50-
1 p.
 artikel
90 P-116 Comparison of DePeCi (dexamethazone, pentoxyfillin, ciprofloxacin) and DePeCi + amifostine withior without G-CSF in myelodysplastic syndromes (MDS) treatment Dwilewicz-Trojaczeki, J.
 2005
 29 S1 p. S68-
1 p.
 artikel
91 P-39 Correlation between apoptosis and SDF-1/CXCR4 system in CD34 positive cells in myelodysplastic syndrome Matsuda, M.
 2005
 29 S1 p. S38-S39
2 p.
 artikel
92 P-46 Cultural methods in the searchof the etiology, pathogenesis and classification of MDS Saralidze, T.
 2005
 29 S1 p. S41-S42
2 p.
 artikel
93 P-64 Cytogenetics abnormalities in MDS patients with autoimmune phenomena Feitosa Pinheiro, R.
 2005
 29 S1 p. S48-
1 p.
 artikel
94 P-74 Danazol in the treatment of myelodysplastic syndrome's (MDS) cytopenias: A retrospective analysis of a series of 223 patients from a single institution Cobol, F.
 2005
 29 S1 p. S52-
1 p.
 artikel
95 P-84 Darbepoetin alpha efficacy in myelodysplastic syndrome Oliva, E.N.
 2005
 29 S1 p. S56-
1 p.
 artikel
96 P-94 Decreased incidence of clonal evolution to myelodysplastic syndrome with monosomy 7 in children with aplastic anemia following reduced duration G-CSF therapy and early indication for BMT from an alternative donor Yagasaki, H.
 2005
 29 S1 p. S59-S60
2 p.
 artikel
97 P-14 Demographic and disease-related prognostic factors in myelodysplastic syndromes classified according to who criteria Malcovati, L.
 2005
 29 S1 p. S29-S30
2 p.
 artikel
98 P-16 Determination of the response toanemia index (RAI) in patients with MDS. Recognition of this parameter as a major predictor of in vivo response to treatment with rh-EPO Symeonidis, A.S.
 2005
 29 S1 p. S30-
1 p.
 artikel
99 P-33 Difference in morphological features between Japanese and German patients with refractory anemia according to the French-American-British classification Misumi, M.
 2005
 29 S1 p. S36-
1 p.
 artikel
100 P-34 Different modalities of bonemarrow blast quantification can influence diagnostic and prognostic evaluation of myelodysplastic syndromes (MDS) Salvi, F.
 2005
 29 S1 p. S37-
1 p.
 artikel
101 P-25 Distinct clinical and laboratoryfeatures of RCMD compared to RA may reflect a multistep pathogenesis of MDS. An analysis of 106 patients with early MDS Cermak, J.
 2005
 29 S1 p. S33-
1 p.
 artikel
102 P-43 Effect of the treatment withCA2 anti-TNFα monoclonal antibody on the bone marrow (BM) progenitor cell reserve and function and stromal cell function in patients with myelodysplastic syndrome (MDS). A study of the Greek mds study group Papadaki, H.A.
 2005
 29 S1 p. S40-
1 p.
 artikel
103 P-63 Effects of alternative splicing and nonsense-mediated mRNA decay on the expression of a variant of GM-CSF receptor beta chain in myelodysplastic syndromes Shikama, Y.
 2005
 29 S1 p. S48-
1 p.
 artikel
104 P-78 Epidemiological survey on myelodysplastic syndromes (MDS) in Piedmont, Italy: Preliminary evaluation of transfusional requirements based on Piedmont MDS registry website Salvi, F.
 2005
 29 S1 p. S53-
1 p.
 artikel
105 P-40 Establishment of cytokine-independent human myelodysplastic cell line and its characterization Chen, B.
 2005
 29 S1 p. S39-
1 p.
 artikel
106 P-53 Evaluation of CD4 and CD8 lymphocytes as normal controls for humara clonality assay in MDS Mitsui, T.
 2005
 29 S1 p. S44-
1 p.
 artikel
107 P-9 Evaluation of dynamic prognostic factors in myelodysplastic syndromes — A single-center analysis Nosslinger, T.M.
 2005
 29 S1 p. S27-S28
2 p.
 artikel
108 P-22 Evaluation of the WHO proposals for the diagnosis of CMML Knipp, S.
 2005
 29 S1 p. S32-
1 p.
 artikel
109 P-114 Exisulind selectively inducesapoptosis via c-jun kinase activation in sAML/MDS Czibere, A.
 2005
 29 S1 p. S67-
1 p.
 artikel
110 P-13 Expression of B7 family molecules on blasts of patients with myelodysplastic syndromes (MDS) and de novo acute myeloid leukemia (AML) Tamura, H.
 2005
 29 S1 p. S29-
1 p.
 artikel
111 P-49 Expression of 7 cases of MDR (multi-drugresistance)1 in MDS cases with progression to overt leukemia Nakagawa, Y.
 2005
 29 S1 p. S43-
1 p.
 artikel
112 P-83 Expression of MIP-1α protein in 65 patients with myelodysplastic syndrome (MDS). A study of the Greek MDS study group Mavrogianni, D.
 2005
 29 S1 p. S55-
1 p.
 artikel
113 P-37 Flow cytometric analysis of cytosolic and mitochondrial ferritins in immature red blood cells from patients with myelodysplastic syndrome Della Porta, M.G.
 2005
 29 S1 p. S38-
1 p.
 artikel
114 P-19 French registry of GFM group Dreyfus, F.
 2005
 29 S1 p. S31-
1 p.
 artikel
115 P-76 Hemoglobin level threshold in myelodysplastic syndrome: Cardiac hypertrophy and quality of life Oliva, E.N.
 2005
 29 S1 p. S52-S53
2 p.
 artikel
116 P-67 Hyperdiploidy in MDS and AML is associated with poor prognosis Balleisen, S.
 2005
 29 S1 p. S49-
1 p.
 artikel
117 P-42 Immediate early response gene 1 (IEX-1) is decreased in CD34+ bone marrow cells from patients with myelodysplastic syndromes Prall, W.C.
 2005
 29 S1 p. S40-
1 p.
 artikel
118 P-23 Immunohistochemistry of P53 and HBF and chromosome analysis are useful for differentiating MDS(RA) from aplastic anemia Sugisaki, C.
 2005
 29 S1 p. S33-
1 p.
 artikel
119 P-71 Immunosuppressive therapy (IST) of patients with myelodysplastic syndromes (MDS) Gritsaev, S.V.
 2005
 29 S1 p. S50-S51
2 p.
 artikel
120 P-80 Improved predictive factors ofresponse for myelodysplastic syndrome patients treated by the combination of erythropoietin and G-CSF Park, S.
 2005
 29 S1 p. S54-
1 p.
 artikel
121 P-35 Incorporation of B2M into riskassessment of patients with MDS improves the discriminatory power of the IPSS: Validation in an independent population of patients Gatto, S.
 2005
 29 S1 p. S37-
1 p.
 artikel
122 P-10 Influence of age and gender on survival in MDS: Importance of an IPSS*gender interaction — A multicenter analysis on 1159 patients Pfeilstocker, M.
 2005
 29 S1 p. S28-
1 p.
 artikel
123 P-8 Influence of smoking on prognosisand cytogenetics in myelodysplastic syndromes Linnemeier, A.
 2005
 29 S1 p. S27-
1 p.
 artikel
124 P-50 Investigation on the cellular origin of fibrous tissue in a case with myelofibrosis Ohashi, H.
 2005
 29 S1 p. S43-
1 p.
 artikel
125 P-91 Is complete or partial monosomy of the chromosome 7 in pediatric patients a separate disease? Ussowicz, M.
 2005
 29 S1 p. S58-S59
2 p.
 artikel
126 P-101 Isolation of the CD34+ progenitorcells in myelodysplastic syndromes with various chromosomal abnormalities: Evidence for involvement in the transformed clone Kyriakous, D.S.
 2005
 29 S1 p. S62-
1 p.
 artikel
127 P-77 Itraconazole capsules versusfluconazole capsules for anti-fungal chemoprophylaxis in patients with myelodysplastic syndromes or acute myeloid leukemia with multilineage dysplasia Ito, Y.
 2005
 29 S1 p. S53-
1 p.
 artikel
128 P-92 JMML and primary immunodeficiency?A coincidence or? Bekassy, A.N.
 2005
 29 S1 p. S59-
1 p.
 artikel
129 P-47 Lack of mutations of the humantelomerase RNA gene (HTERC) in myelodysplastic syndromes Ohyashiki, K.
 2005
 29 S1 p. S42-
1 p.
 artikel
130 P-121 Lenalidomide (CC-5013; revlimid™)-inducedred blood cell (RBC) transfusion-independence (TI) responses in low-/INT-1-risk patients with myelodysplastic syndromes (MDS): Results of the multicenter mds 002 study Raza, A.
 2005
 29 S1 p. S70-
1 p.
 artikel
131 P-93 Leukemic transformaton in fanconi anemia Matsumoto, M.
 2005
 29 S1 p. S59-
1 p.
 artikel
132 P-44 Longitudinal assessment ofhematopoietic abnormalities following autologous hematopoietic cell transplantation for lymphoma and association with risk of therapy-related myelodysplasia Bhatia, R.
 2005
 29 S1 p. S41-
1 p.
 artikel
133 P-120 Low dose all-trans-retinoic acid and androgen therapy for patients with myelodysplastic syndrome Guan, M.
 2005
 29 S1 p. S70-
1 p.
 artikel
134 P-109 MAG mobilization of peripheral blood stem cells and autologous peripheral blood stem cell transplantation in 43 patients with hematopoietic malignancies Qiu, H.-y.
 2005
 29 S1 p. S65-
1 p.
 artikel
135 P-73 Marked improvement produced after laparoscopic splenectomy in hypoplastic refractory anemia (case report) Gologa, R.
 2005
 29 S1 p. S51-
1 p.
 artikel
136 P-12 Marrow progenitors in myelodysplastic syndrome (MDS) demonstrate an aberrant cell cycle and DNA damage Head, D.R.
 2005
 29 S1 p. S29-
1 p.
 artikel
137 P-88 Methylation status of the P15 and P16 genes in pediatric myelodysplastic syndrome and juvenile myelomonocytic leukemia Hasegawa, D.
 2005
 29 S1 p. S57-
1 p.
 artikel
138 P-60 Molecular analysis of ltr of feline leukemia virus derived from cats with myelodysplastic syndromes and analysis of disease potential of the virus Hisasue, M.
 2005
 29 S1 p. S47-
1 p.
 artikel
139 P-90 Mutations in N-RAS and PTPN11 inJapanese patients with juvenile myelomonocytic leukemia Yamamoto, T.
 2005
 29 S1 p. S58-
1 p.
 artikel
140 P-85 Myelodysplastic syndrome with bone marrow hypoplasia is associated with much higher frequency of apoptosis in CD34+ cells Oyake, T.
 2005
 29 S1 p. S56-
1 p.
 artikel
141 P-98 Naive B lymphocytes expansion in bone marrow and peripheral blood after successful unrelated cord blood transplantation for an adult patient with advanced myelodysplastic syndrome Toubai, T.
 2005
 29 S1 p. S61-
1 p.
 artikel
142 P-45 NF-κB is a potential therapeutictarget in high risk MDS: Induction of apoptosis by bortezomib and BAY 11-7082 Braun, T.
 2005
 29 S1 p. S41-
1 p.
 artikel
143 P-117 Orthomolecular vitamin D3in low-risk myelodysplastic syndrome (MDS): Preliminary results Molnar, I.
 2005
 29 S1 p. S69-
1 p.
 artikel
144 P-106 Pharmacodynamic study of 5-azacytidine Khan, R.
 2005
 29 S1 p. S64-
1 p.
 artikel
145 P-51 Phosphatidylinositol glycan-class a (PIG-A) gene mutations in patients with aplastic anemia (AA) and myelodysplastic syndrome (MDS) Noji, H.
 2005
 29 S1 p. S43-S44
2 p.
 artikel
146 P-118 Pilot trial of the histone deacetylase inhibitor depsipeptide in patients with acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS) Klimek, V.M.
 2005
 29 S1 p. S69-
1 p.
 artikel
147 P-81 Possible involvement of fractalkine/CX3CR1 system in dyshematopoiesis in MDS using perforin/granzyme-positive MDS-derived cytotoxic T cell line, K2-MDS Morita, Y.
 2005
 29 S1 p. S54-S55
2 p.
 artikel
148 P-111 Preliminary experience of oral arsenic trioxide in the treatment of refractory myeloid leukaemia Au, W.Y.
 2005
 29 S1 p. S66-
1 p.
 artikel
149 P-5 Presence of peripheral blasts in RAand RARS predicts an unfavourable outcome Knipp, S.
 2005
 29 S1 p. S26-
1 p.
 artikel
150 P-17 Prevalence of HTLV-I carriers among patients with MDS RAEB and AML Matsushita, K.
 2005
 29 S1 p. S30-S31
2 p.
 artikel
151 P-7 Prognostic factors in refractory anemia according to the French-American-British classification Matsuda, A.
 2005
 29 S1 p. S27-
1 p.
 artikel
152 P-4 Prognostic impact of bone marrow cellularity in myelodysplastic syndromes on overall survival Knipp, S.
 2005
 29 S1 p. S26-
1 p.
 artikel
153 P-11 Prognostic significance of deletion of the long arm of chromosome 20 in patients with myelodysplastic syndrome (MDS). A study of the Greek MDS study group Galanopoulos, A.G.
 2005
 29 S1 p. S28-
1 p.
 artikel
154 P-2 Prognostic value of bone marrowblast cells and karyotype in myelodysplastic syndrome Gritsaev, S.V.
 2005
 29 S1 p. S25-
1 p.
 artikel
155 P-30 Prospective validation of the WHO classification of primary myelodysplastic syndromes Kuendgen, A.
 2005
 29 S1 p. S35-
1 p.
 artikel
156 P-59 Proteomics approach to identifyingproteins abnormally expressed in neutrophils in patients with myelodysplastic syndrome Kazama, H.
 2005
 29 S1 p. S46-S47
2 p.
 artikel
157 P-31 3q Cytogenetic aberrations in a series of 223 myelodysplastic syndrome (MDS)/chronic myelomonocytic leukemia (CMML) patients from a single institution Cobol, F.
 2005
 29 S1 p. S35-S36
2 p.
 artikel
158 P-27 Quantitative and easy evaluationof apoptosis using Annexin-V by flow cytometry in myelodysplastic syndrome Masamoto, I.
 2005
 29 S1 p. S34-
1 p.
 artikel
159 P-29 RA and RARS with thrombocytosis:Mixed myelodysplastic/myeloproliferative disorder? Knipp, S.
 2005
 29 S1 p. S35-
1 p.
 artikel
160 P-48 rap1b point mutations homologousto activating RAS mutations are uncommon during MDS leukemic transformation Gyan, E.
 2005
 29 S1 p. S42-
1 p.
 artikel
161 P-68 Rare chromosomal abnormalitiesin myelodysplastic syndromes Kyriakou, D.S.
 2005
 29 S1 p. S49-S50
2 p.
 artikel
162 P-32 Reclassification of FAB chronic myelomonocytic leukemia (CMML) according to the World Health Organization (WHO) criteria: An analysis of 41 patients from a single institution Cobol, F.
 2005
 29 S1 p. S36-
1 p.
 artikel
163 P-97 Reduced-intensity allogeneichematopoietic stem cell transplantation for myelodysplastic syndrome Nakamura, R.
 2005
 29 S1 p. S61-
1 p.
 artikel
164 P-28 Refractory anemia with excess of blasts (RAEB): Analysis of reclassification of the WHO Knipp, S.
 2005
 29 S1 p. S34-S35
2 p.
 artikel
165 P-1 Relationship between GSTT1, GSTM1and NQ01 genes polymorphisms and myelodysplastic symdromes Xiao, Z.
 2005
 29 S1 p. S25-
1 p.
 artikel
166 P-112 Results of a phase II trial with valproic acid (VPA) alone or in combination with all-trans-retinoic acid (ATRA) in 71 patients with myelodysplastic syndromes or SAML/MDS Kuendgen, A.
 2005
 29 S1 p. S66-
1 p.
 artikel
167 P-108 Re-treatment results insecond remission of MDS with previous response to low-dose 5-aza-2′-deoxycytidine (decitabine) Ruter, B.
 2005
 29 S1 p. S65-
1 p.
 artikel
168 P-26 Structural parameters provided by blood analysis with Sysmex XE 2100N analyzer are helpful for the diagnosis of MDS Leroux, G.
 2005
 29 S1 p. S34-
1 p.
 artikel
169 P-52 Study of DNA repair geneexpression in MDS patients with shortened telomeres and multiple chromosomal abnormalities by array-based comparative genomic hybridization (A-CGH) Gondek, L.
 2005
 29 S1 p. S44-
1 p.
 artikel
170 P-38 Subacute myeloid leukemia inmyelodysplastic syndromes Qiu, J.-y.
 2005
 29 S1 p. S38-
1 p.
 artikel
171 P-21 Subgroups of mixedmyelodysplastic and myeloproliferative syndromes (MDS/MPS) Neuwirtova, R.
 2005
 29 S1 p. S32-
1 p.
 artikel
172 P-62 Telomerase activity inmyelodysplastic syndrome Fu, C.C.
 2005
 29 S1 p. S47-S48
2 p.
 artikel
173 P-61 Telomere attrition of lymphocytes in myelodysplastic syndrome: Correlation with clinical findings Sashida, G.
 2005
 29 S1 p. S47-
1 p.
 artikel
174 P-54 Telomere length control bytelomere binding proteins, TRF1, TRF2 and POT1, in myelodysplastic syndrome Honda, S.
 2005
 29 S1 p. S44-S45
2 p.
 artikel
175 P-110 Thalidomide for the treatmentof low risk myelodysplasia: The ThaI-SMD-200 trial Bouscary, D.
 2005
 29 S1 p. S65-S66
2 p.
 artikel
176 P-113 The efficacy and tolerabilityof ICL670, a once-daily oral iron chelator, in patients with myelodysplastic syndrome (MDS) and iron overload Gattermann, N.
 2005
 29 S1 p. S67-
1 p.
 artikel
177 P-99 The evolution of the strategy for MDS/JMML in Osaka Medical Center for maternal and child health Sawada, A.
 2005
 29 S1 p. S61-S62
2 p.
 artikel
178 P-87 The molecular organization of erythrocyte membrane of children suffering initial myelodysplastic syndrome Klimkovich, N.N.
 2005
 29 S1 p. S57-
1 p.
 artikel
179 P-75 The use of erythropoietin inmyelodysplastic syndromes (MDS): Impact on fatigue and quality of life Laudon Thomas, M.
 2005
 29 S1 p. S52-
1 p.
 artikel
180 P-105 The value of oral cytarabine ocfosfate and etoposide in the treatment of elderly patients with high-risk myelodysplastic syndromes Horikoshi, A.
 2005
 29 S1 p. S64-
1 p.
 artikel
181 P-79 Transfusion and iron overload (IO)in MDS: Impact of infusion chelation therapy (ICT) on quality of life (QoL) and adherence Abetz, L.N.
 2005
 29 S1 p. S54-
1 p.
 artikel
182 P-3 Transfusion dependency:Independent prognostic factor for patients with myelodysplastic syndrome Wong, L.
 2005
 29 S1 p. S25-S26
2 p.
 artikel
183 P-107 Treatment of patients with high-risk MDS and sAML with Bendamustin Knipp, S.
 2005
 29 S1 p. S64-S65
2 p.
 artikel
184 P-36 Trisomy 8 alone in myelodysplasticsyndromes: Recognition of the common clinico-hematologic features from 109 patients Symeonidis, A.S.
 2005
 29 S1 p. S37-S38
2 p.
 artikel
185 P-24 Usefullness of PET (PositronEmission Tomography) in the discrimination between hypoplastic myelodysplastic syndromes and aplastic anemia Takatoku, M.
 2005
 29 S1 p. S33-
1 p.
 artikel
186 P-102 Use of blood stem cellsimproves results of allogeneic transplantation in patients with myelodysplastic syndrome/secondary acute myelogenous leukemia (MDS/SAML) and a poor-risk karyotype Nevill, T.J.
 2005
 29 S1 p. S63-
1 p.
 artikel
187 Results of an international phase 2study of the oral farnesyl transferase inhibitor (FTI) tipifarnib (ZARNESTRA®) in patients with high-risk myelodysplastic syndrome (MDS) Fenaux, P.
 2005
 29 S1 p. S71-
1 p.
 artikel
                             187 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland